You are here: Industry Insights > monoclonal antibody

News List

Shire expands broad monoclonal antibody research platform cphi-online
July 20, 2017
Shire obtains worldwide license to pursue development and commercialization of a novel, potentially differentiated, pre-clinical bi-specific antibody candidate for Hemophilia A.
When Will Chinese “Rituxan” be Marketed in Compete with More Than a Dozen Applying for anti-CD20 en-cphi.cn
July 14, 2017
CFDA released the 2016 Annual Report of Release of Biological Products written by the National Institutes for Food and Drug Control of China on July 4, which has made statistics of biological products included in release management.
AstraZeneca Updates Stratos 1 Phase III Trial of Tralokinumab americanpharmaceuticalreview
May 11, 2017
AstraZeneca and MedImmune announced tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody.
Glenmark Pharma initiates clinical investigation for GBR 310 financialexpress
April 26, 2017
GBR 310 is a recombinant DNA-derived humanised immunoglobulin G1 kappa monoclonal antibody
Sanofi and Lonza in $285mn Biologics Pact contractpharma
March 07, 2017
A large-scale facility, to be built in Visp, Switzerland, will be established through a joint venture
Sanofi, MedImmune in RSV Alliance contractpharma
March 06, 2017
MedImmune to lead development, AstraZeneca retains manufacturing activities, Sanofi-Pasteur will lead commercialization
Fujifilm Diosynth Biotechnologies Launches New Service Offering contractpharma
March 03, 2017
Will support development and cGMP monoclonal antibody production
Sanofi, Lonza join hands to build biologics plant biospectrumasia
March 01, 2017
The joint venture combines the strong biologics development pipeline of Sanofi with the expertise of Lonza to design, construct, start-up and operate a state-of-the-art large-scale mammalian cell culture facility
Sanofi, Lonza form monoclonal antibody production partnership firstwordpharma
February 28, 2017
Sanofi announced Monday a partnership with Lonza to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production, with an initial investment of around 290 million Swiss francs ($288 million) split equally between the
Valeant's treatment for plaque psoriasis gets FDA thumbs up for Siliq cphi-online
February 20, 2017
More than 50% of patients in three clinical studies who used Siliq achieved total skin clearance within a year.

Previous page 1 2 3 4 5 6 Next page